Justification Document for the Selection of a CoRAP Substance

Substance Name (public name)	: 1,1,1,3,5,5,5-heptamethyl-3- [(trimethylsilyl)oxy]trisiloxane
EC Number:	241-867-7
CAS Number:	17928-28-8
Authority:	UK MSCA
Addiority	UK MSCA
Date:	22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Table of Contents

1		OF THE SUBSTANCE or identifiers of the substance	3 3
2	OVERVIE	W OF OTHER PROCESSES / EU LEGISLATION	5
3	3.1 Class 3.1.1	INFORMATION (INCLUDING CLASSIFICATION) sification Harmonised Classification in Annex VI of the CLP Self classification	6 6 6
	_	Proposal for Harmonised Classification in Annex VI of the 6	U
4	4.1 Tonr	TION ON (AGGREGATED) TONNAGE AND USES nage and registration status rview of uses	7 7 7
5.	5.1.Lega 5.2. Sele CoR	ATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE al basis for the proposal ection criteria met (why the substance qualifies for being in AP) al grounds for concern to be clarified under Substance	8 8 n 8
	Eval 5.4 Preli	uation minary indication of information that may need to be lested to clarify the concern	8 9
	-	ntial follow-up and link to risk management	9

1 IDENTITY OF THE SUBSTANCE

1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	1,1,1,3,5,5,5-heptamethyl-3- [(trimethylsilyl)oxy]trisiloxane
IUPAC name (public):	1,1,1,3,5,5,5-heptamethyl-3- [(trimethylsilyl)oxy]trisiloxane
Index number in Annex VI of the CLP Regulation:	Not applicable
Molecular formula:	C ₁₀ H ₃₀ O ₃ Si ₄
Molecular weight or molecular weight range:	310.69
Synonyms:	TMF-1.5

Structural formula:

1.2 Similar substances/grouping possibilities

The structurally related chemicals hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane and dodecamethyltetrasiloxane could be included to form a category for evaluation.

Name	CAS No	EC No	Comments
Hexamethyldisiloxane (L2)	107-46-0	203-492-7	Registered, SEV by
			UKCA in 2013
Octamethyltrisiloxane	107-51-7	203-497-4	Registered, SEV by
(L3)			UKCA in 2015
Decamethyltetrasiloxane (L4)	141-62-8	205-491-7	Registered, SEV by
			UKCA in 2015
Dodecamethyltetrasiloxane	141-63-9	205-492-2	Registered, SEV by
(L5)			UKCA in 2015

Structural formula:

Hexamethyldisiloxane (L2)	Si Si
Octamethyltrisiloxane (L3)	 SiSiSi
Decamethyltetrasiloxane (L4)	
Dodecamethyltetrasiloxane (L5)	$ \sum_{i=0}^{ } \sum_{$

2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

RMOA		\Box Risk Management Option Analysis (RMOA)	
	Evaluation	Compliance check, Final decision	
		Testing proposal	
ssses	ú	CoRAP and Substance Evaluation	
REACH Processes	sation	🗆 Candidate List	
REA(Authorisation	Annex XIV	
	Restri -ction	Annex XVII	
Harmonised C&L		□ Annex VI (CLP) (see section 3.1)	
esses other slation		Plant Protection Products Regulation Regulation (EC) No 1107/2009	
Processes under other EU legislation		Biocidal Product Regulation Regulation (EU) 528/2012 and amendments	
us cion		 Dangerous substances Directive Directive 67/548/EEC (NONS) 	
Previous legislation		 Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS) 	
UNEP) ockholm nvention (POPs otocol)		□ Assessment	
(UNEP) Stockholm convention (POPs Protocol)	In relevant Annex		
Other processes / EU legislation	Other (provide further details below)		

Table: Completed or ongoing processes

D4 and D5 have been agreed to meet the PBT/vPvB criteria, which may affect the supply of decamethyltetrasiloxane if this is used as a substitute in the future.

L2, L3, L4 and L5 are already subject to substance evaluation under REACH.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

The substance is not classified in Annex VI of Regulation (EC) No 1272/2008

3.1.2 Self classification

- In the registration: not classified
- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Flam. Liq. 3H226Skin Irrit. 2H315Eye Irrit. 2H319STOT SE 3H335 (target organ: "respiratory tract" or "not provided")

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

No proposal according to registry of intention (checked May 2015)

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES¹

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site				
⊠ Full registration(s) (Art. 10)		\Box Intermediate registration(s) (Art. 17 and/or 18)		
Tonnage band (as per dissemina	ation s	ite)		
🗆 1 – 10 tpa	⊠ 1	0 – 100 tpa	🗆 100 – 1000 tpa	
🗆 1000 – 10,000 tpa		0,000 – 100,000 tpa	□ 100,000 - 1,000,000 tpa	
□ 1,000,000 - 10,000,000 tpa	□ 1 tpa	0,000,000 - 100,000,000	□ > 100,000,000 tpa	
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential			Confidential	
Joint submission				

4.2 Overview of uses

The following uses are identified on the ECHA dissemination site: personal care products, and laboratory reagent. These cover industrial use, professional use and consumer use.

The primary interest in the substance evaluation is the use of personal care products as this is potentially a down-the-drain source of environmental exposure. The significance of the other use will be assessed as part of the evaluation. It is expected that there will be similarities with the exposure assessments of HMDS (L2) (already evaluated), L3-L5 (being evaluated in 2015) and the cyclic siloxanes D4 and D5 (both subject to a risk management options analysis).

Table: Uses

Part 1:

	\boxtimes	\boxtimes	\boxtimes	\boxtimes	Article	Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		

¹ Based on ECHA dissemination site accessed 18th May 2015.

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

5.1. Legal basis for the proposal

 \boxtimes Article 44(2) (refined prioritisation criteria for substance evaluation)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

 \Box Fulfils criteria as CMR/ Suspected CMR

□ Fulfils criteria as Sensitiser/ Suspected sensitiser

□ Fulfils criteria as potential endocrine disrupter

⊠ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB

 \Box Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)

 \boxtimes Fulfils exposure criteria

□ Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns CMR Suspected CMR² □ Potential endocrine disruptor $\Box C \Box M \Box R$ $\Box C \Box M \Box R$ □ Sensitiser \Box Suspected Sensitiser² \Box Other (please specify below) \boxtimes Suspected PBT/vPvB² □ PBT/vPvB Exposure/risk based concerns \Box Exposure of sensitive \boxtimes Wide dispersive use Consumer use populations Exposure of □ Exposure of workers \Box Cumulative exposure environment □ High RCR ☐ High (aggregated) tonnage \Box Other (please specify below)

<u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/uspected consisting properties (not classified according to CLP harmonized or registrant self-classified according to CLP inventory)

properties/suspected sensitising properties (not classified according to CLP harmonized or registrant selfclassification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

The substance screens as vPvB based on the results from a ready biodegradation study and predicted log Kow. The registrant's PBT assessment indicates the substance "may be persistent and very persistent in sediment". However, a request to waive the environmental simulation studies for water, sediment and soil for the substance have been included in the registration dossier.

Characteristics of other siloxanes such as D4, D5 and HMDS (L2) suggest that this group of substances has the potential to be persistent in sediment. Therefore as well as clarifying P properties, sediment risks will also be investigated.

The measured bioconcentration factor in fish at steady state is 3500 L/kg according to the registration dossier. This exceeds the Annex XIII B criterion. It is not known if this value has been corrected for growth or lipid normalised, and it is possible that the value may be higher once this has been done. The range of BCF results is between 1500 – 9600 L/kg.

The chronic fish endpoint is fulfilled using read-across to a test that only investigated mortality. The validity of this test will be assessed as the endpoint is important for the T assessment.

1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]trisiloxane is registered with uses including professional and consumer personal care products, which suggests a wide dispersive use pattern. As the substance could be a potential replacement for D4 and D5, the supply volume of 1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy] could increase if uses of those substances are restricted.

The evaluation will be targeted to the environment but during the PBT assessment the human health endpoints relevant to the T criterion will be assessed.

5.4 Preliminary indication of information that may need to be requeste to clarify the concern

\square Information on toxicological properties	Information	\Box Information on physico-chemical properties			
$oxedsymbol{\boxtimes}$ Information on fate and behaviour	🛛 Information	☐ Information on exposure			
☑ Information on ecotoxicological properties	Information	□ Information on uses			
Information ED potential	🗌 Other (prov	\Box Other (provide further details below)			
Testing to assess persistence in sediment, for example OECD 308 Aerobic and Anaerobic Transformation in Aquatic Sediment Systems. Further information on releases from relevant parts of the life cycle (may include a request for monitoring data). Further data to clarify any sediment risks. 5.5 Potential follow-up and link to risk management					
, j					
□ Harmonised C&L □ Restriction □ Authorisation □ Other (provide further details)					
To be determined following substance evaluation. However, if the PBT/vPvB concern is confirmed, it will not be desirable to allow the replacement of D4 and D5 by this substance in personal care products, so a similar restriction approach might be required.					